Skip to main content
Clinical Trials/DRKS00016552
DRKS00016552
Completed
Phase 3

Effects of foreign language learning on cognition in healthy older adults - SpeAK study

etzwerk Alternsforschung der Ruprecht-Karls-Universität Heidelberg0 sites34 target enrollmentFebruary 11, 2019
ConditionsCognition

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Cognition
Sponsor
etzwerk Alternsforschung der Ruprecht-Karls-Universität Heidelberg
Enrollment
34
Status
Completed
Last Updated
last year

Overview

Brief Summary

Foreign language learning did not significantly improve primary or secondary outcomes, neither immediately nor 3 months after the language course. However, moderation analyses revealed that participants with lower global baseline cognition tended to improve more on response inhibition than individuals with higher baseline cognition. This relationship was not evident in the waiting list control group.

Registry
who.int
Start Date
February 11, 2019
End Date
July 31, 2020
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
etzwerk Alternsforschung der Ruprecht-Karls-Universität Heidelberg

Eligibility Criteria

Inclusion Criteria

  • German mother tongue
  • \- Monolingual (no fluency and more than occasional use of any other language according to self\-disclosure; Additional information: Evaluation of monolingualism according to LSBQ score \[Bialystok et al., 2018])
  • \- Living independently
  • \- No full\-time employment (secondary employment of a maximum of 50% permitted)
  • \- To be motivated to effectively participate in the study and to sign the consent form in agreement with the local ethic committee

Exclusion Criteria

  • \- A1 or higher level of Spanish according to the Common European Framework of Reference for Languages
  • \- Good or better knowledge of Romanic languages (Italian, French, Latin, Portuguese) according to the Common European Framework of Reference for Languages
  • \- Below\-average cognitive performance according to age (CFD S1 from Schuhfried GmbH: No subtest z \= \-1\.5 \[PR \= 6])
  • \- Impaired or uncorrected vision
  • \- Colour blindness
  • \- Impaired hearing
  • \- Self\-reported current or previous neurological disease including stroke, mild cognitive impairment, dementia, Parkinson's disease, epilepsy, multiple sclerosis, encephalitis)
  • \- Self\-reported current or previous mental disorder including anxiety disorder, depression, schizophrenia, alcohol or substance dependence
  • \- Loss of consciousness for more than five minutes
  • \- Current musical activity for more than five hours per week

Outcomes

Primary Outcomes

Not specified

Similar Trials